To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Nanobodies, promising biotherapeutic agents, may trigger undesirable immune reactions. A team from SIMoS demonstrates, using a sensitive assay on human T lymphocytes, that this risk exists for certain nanobodies and can be reduced through sequence humanization. These findings highlight the importance of assessing immunogenicity alongside therapeutic efficacy.
Researchers from the MIND team (NeuroSpin) and the Neuroscience Center in Helsinki describe a machine learning model that simplifies the interpretation of stereo-electroencephalography (SEEG) data acquired during the presurgical evaluation of drug-resistant epilepsy. This approach improves and facilitates the localization of the epileptogenic network.
Researchers from our DMTS department have published a study providing the first proof of concept for a CAR-macrophage therapy targeting the endothelin B receptor, which is overexpressed in melanoma cells.
Researchers from the DMTS have developed a method for exploring the chemical exposome in large, complex mass spectrometry datasets. They applied it to the analysis of meconium samples from a cohort.
Researchers from BAOBAB (NeuroSpin) have demonstrated that cortical folding is indeed a biomarker of brain development and that its genetic influences can be detected using deep learning methods.
A collaborative study between the BIAM and Joliot (SPI/DMTS) institutes demonstrates the feasibility of near-complete whole-body carbon-13 isotopic labeling in mice and lays the foundation for a global, quantitative, and unbiased metabolomics approach. This unprecedented strategy could also enable the investigation of certain metabolic troubles.
DMTS teams have characterised 17 monoclonal antibody-candidates targeting ricin using two original biophysical approaches. The identification of ricin residues involved in functional antibody recognition paves the way for the development of powerful monoclonal therapeutic antibodies against this natural toxin, which is a bioterrorism agent.
The CEA is revealing a series of in vivo human brain images acquired with the Iseult MRI machine and its unmatched 11.7 teslas magnetic field strength. This success is the fruit of more than 20 years of R&D as part of the Iseult project, with one pillar goal being to design and build the world’s most powerful MRI machine. Its ambition is to study healthy and diseased human brains with an unprecedented resolution, allowing us to discover new details relating to the brain’s anatomy, connections, and activity.
In an article in the New York Times, Stanislas Dehaene (NeuroSpin director) and Mathias Sablé-Meyer (PhD student) discuss recent results obtained in collaboration with the Collège de France, the CNRS and the University of Paris 8 that show that humans have a universal capacity to understand abstract geometric concepts.
September 2021, the 11.7 Tesla MRI of the Iseult project, the most powerful in the world for human imaging, has just unveiled its first images.
Le projet EXPERIENCE cherche à utiliser la réalité virtuelle pour améliorer la vie quotidienne en permettant de nouvelles formes d’interaction sociale et d’expression personnelle.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.
